]>
IRCT20200406046968N3 IRCT 2020-05-08 Zist Daru Danesh Company effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital 2020-04-29 anticipated 60 Complete https://irct.ir/trial/47152 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done by permuted (balanced) block randomization method. At the beginning, we will define quadruple blocks with group (a) and group (b) arrangements, and then we will select each of the blocks using the table of random numbers, and after each black determination, prepare 4 patients in the arrangement of(A) and (B) group in the selected block enrolled to the study. Then 4 other patients will be selected through the other block. We will Continue this process to complete patients. 2 COVID-19 diseaese. Intervention 1: Intervention group: 30 COVID-19 patients with inclusion criteria will be treated with 250 micro grams of betafron (Zifron Zist Darou Danesh) Subcutaneously every other day up to 10 days or 5 dosages in addition to antivirals including hydroxychloroquine 400 mg,bid stat. and Kaletra 2 tablet bid for 10 days. Intervention 2: Control group: 30 COVID-19 patients will be treated only with antivirals including hydroxychloroquine 400 mg,bid stat and Kaletra 2 tablet bid for 10 days. Yes - There is a plan to make this available What will be shared: All data related to the study of the effect of interferon-beta 1 (zifron) on clinical improvement and prognosis of patients with COVID-19 will be shared in Imam Reza (AS) Hospital in Tabriz. When: Since the summer of 1399 To whom: Researchers and all treatment staff Conditions: For treatment Where to obtain: Dr. Mikaeili haleh How to obtain: After finishing the work and getting the result Comments:
public Mikaeili Haleh
3rd Floor, Central Building, University Street, Tabriz, Iran
Tabriz Iran (Islamic Republic of) 5157679746 +98 41 3329 6024 halehmikaeili@gmail.com Tabriz University of Medical Sciences scientific Mikaeili Haleh
3rd Floor, Central Building, University Street, Tabriz, Iran
Tabriz Iran (Islamic Republic of) 5157679746 +98 41 3329 6024 halehmikaeili@gmail.com Tabriz University of Medical Sciences Iran (Islamic Republic of) respiratory rate> 24 / min pao2 / Fio2< 300 no limit no limit Both Pregnancy history of Sensitivity to interferon-beta 1 compounds (zifron) History of advanced liver disease and liver enzymes three times normal history of severe depression or suicidal thought U07.2 COVID-19, virus not identified Treatment - Drugs Treatment - Drugs Intervention group: 30 COVID-19 patients with inclusion criteria will be treated with 250 micro grams of betafron (Zifron Zist Darou Danesh) Subcutaneously every other day up to 10 days or 5 dosages in addition to antivirals including hydroxychloroquine 400 mg,bid stat. and Kaletra 2 tablet bid for 10 days. Control group: 30 COVID-19 patients will be treated only with antivirals including hydroxychloroquine 400 mg,bid stat and Kaletra 2 tablet bid for 10 days. Oxygenation. Timepoint: daily. Method of measurement: pulse oximetery. P/F ratio. Timepoint: daily. Method of measurement: ABG. Need for mechanical ventilation. Timepoint: daily. Method of measurement: file. In hospital mortality. Timepoint: daily. Method of measurement: file. Zist Daru Danesh Company Approved 2020-04-13 Regional Research Ethics Committee (Humanities Studies) Tabriz / Golgasht St. / Tabriz University of Medical Sciences Central Building No. 2 / Third Floor Deputy of Research and Technology Tabriz East Azarbaijan Iran (Islamic Republic of)